Haemophilia A (HA) and B (HB) are X-linked hereditary bleeding disorders caused by lack
of activity of coagulation factors VIII (FVIII) or IX (FIX), respectively. Besides conventional …

In the ongoing pandemic of coronavirus disease 2019 (COVID-19), the novel virus SARS-
CoV-2 (severe acute respiratory syndrome coronavirus 2) is infecting a naïve population …

Hemophilia A (HA) is a rare bleeding disorder caused by deficiency/dysfunction of the FVIII
protein. As current therapies based on frequent FVIII infusions are not a definitive cure, long …

Advances in haematological therapies for people with complex or rare inherited bleeding
disorders (IBD) have resulted in them living longer, retaining their natural teeth with greater …

Hemophilia A is a bleeding disorder that results from coagulation factor VIII (FVIII) deficiency,
which can be treated via substitution therapy using FVIII concentrates. However, the …

Human coagulation factor VIII (FVIII) is a key co-factor in the clotting cascade, the deficiency
of which leads to Hemophilia A. Human plasma-derived (pdFVIII) and recombinant FVIII …

Background Fc-fusion proteins have been successfully developed for therapeutic purposes,
but are also a promising platform for the fast generation and purification of immunogens …

Introduction Hemophilia A (HA) is the most common X-linked bleeding disorder, occurring in
1 in 5,000 live male births and affecting> 1 million individuals worldwide. Although advances …

Inhibitor development is the most severe complication of hemophilia A (HA) care and is
associated with increased morbidity and mortality. This study aimed to use a novel …

Objective: To investigate the perioperative management of patients with hemophilia A (HA)
who undergo cardiac surgery. Design Retrospective analysis of the published literature …